Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

765446

registered interest
date	06/10/2017
answering body	Department for Communities and Local Government
answering dept id	7
answering dept short name	Communities and Local Government
answering dept sort name	Communities and Local Government
hansard heading	Department for Communities and Local Government: Written Questions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Communities and Local Government, when he plans to respond to Question 9514, tabled on 7 September 2017 by the hon. Member for Denton and Reddish.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	106035
answer	answer is ministerial correction date of answer 16/10/2017 answer text <p>I refer the hon. Member for Denton and Reddish to the answer I gave to Question UIN 9514 on Friday 13 October 2017.</p> answering member constituency Reading West answering member printed Alok Sharma question first answered 16/10/2017 12:47:41 answering member 4014 label Biography information for Sir Alok Sharma
tabling member	1506 label Biography information for Andrew Gwynne

765447

registered interest
date	06/10/2017
answering body	Prime Minister
answering dept id	23
answering dept short name	Prime Minister
answering dept sort name	Prime Minister
hansard heading	Raif Badawi
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Prime Minister, what discussions she had on the case of Raif Badawi during her meeting with the Saudi Arabian Minister for Foreign Affairs in September 2017; and if she will make a statement.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	106251
answer	answer is ministerial correction date of answer 11/10/2017 answer text <p>This Government stands up for and strongly supports the freedom of expression. We remain concerned about the case of Raif Badawi and we continue to raise it at a very senior level.</p> answering member constituency Maidenhead answering member printed Mrs Theresa May question first answered 11/10/2017 12:42:09 answering member 8 label Biography information for Mrs Theresa May
tabling member	1506 label Biography information for Andrew Gwynne

765448

registered interest
date	06/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy: Sodium Valproate
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what support the Government plans to provide to children and young adults affected by valproate after their birth (a) now and (b) over the next 10 years.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	106362
answer	answer is ministerial correction date of answer 16/10/2017 answer text <p>Valproate is an effective treatment for epilepsy and bipolar disorder but should only be used in girls and women of childbearing potential if other treatments are ineffective or not tolerated. For some women there may be no other treatment option. Because of ongoing concerns about women’s awareness of the risks, the Medicines and Healthcare products Regulatory Agency (MHRA) has worked with professional bodies, voluntary organisations and patient groups to develop a set of materials to aid communication between health professionals and women and girls.</p><p>The valproate toolkit comprises booklets for healthcare professionals, a reminder card and a guide for women, a checklist for prescribers and clear package labelling carrying a prominent warning about use in pregnancy. The MHRA continues to work with stakeholders to disseminate information and ensure compliance with the statutory advice. On 6 April 2017, NHS Improvement and MHRA sent a Patient Safety Alert through the NHS Central Alerting System to further highlight risks to the unborn child and support the safety of girls and women taking valproate. The alert directs organisations to undertake systematic identification of women and girls taking valproate and to use the MHRA resources to support them to make informed choices. Consistent action was taken in Scotland, Wales, and Northern Ireland.</p><p>The impact of the measures taken is being monitored and studies show a steady decline in prescribing to women in childbearing potential. The adequacy of measures taken to date across Europe is being reviewed in a Europe-wide review that started in March 2017. There are ongoing discussions at official level as the review progresses. An expert working group of the Commission on Human Medicines has been convened to inform the United Kingdom position during the ongoing European Union review and consider other measures which may be required across the healthcare system to ensure compliance with the regulatory position in clinical practice.</p><p>France has its own legislation that allows for a state funded compensation scheme for medical accidents and they have amended this to include claims from those affected by valproate. We understand that this has been operational from June 2017. We are monitoring developments in France and do not feel that commissioning research is necessary at this time. We are not aware of similar action in other member states. There is currently no proposal to establish a care compensation plan specifically for those affected by valproate in the UK. However, the Government has great sympathy for those families who have been affected by the use of valproate in pregnancy. There is support available for families with children born with a disability. The Children and Families Act 2014 introduced a new statutory framework for local authorities and clinical commissioning groups (CCGs) to work together to secure educational, health and social care services for children and young people up to the age of 25 who have special educational needs or a disability (SEND).</p><p>Local authorities and CCGs must commission services jointly around a set of locally agreed outcomes to ensure that the needs of children and young people with SEND are met. Local authorities must also publish a clear, transparent ‘local offer’ of services available which has been developed for, and with, parents and young people. The reforms introduced by the Act are designed to reduce health inequalities, improve the experiences of children and young people with SEND, and their families, and deliver integrated services to achieve improved outcomes.</p><p>The Parliamentary Under Secretary of State for Health (Lord O’Shaughnessy) is meeting with the Chair of the All-Party Parliamentary Group on Anti-epileptic Drugs in Pregnancy to discuss these issues later this year; members of the Independent Fetal Anti Convulsant Trust may wish to attend also.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 106219 106221 106222 106272 106363 106364 106365 106366 106367 question first answered 16/10/2017 16:28:59 answering member 4067 label Biography information for Steve Brine
tabling member	1506 label Biography information for Andrew Gwynne

765449

registered interest
date	06/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy: Sodium Valproate
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will meet people who have been harmed by sodium valproate during pregnancy; and what steps he has to provide compensation to such people.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	106363
answer	answer is ministerial correction date of answer 16/10/2017 answer text <p>Valproate is an effective treatment for epilepsy and bipolar disorder but should only be used in girls and women of childbearing potential if other treatments are ineffective or not tolerated. For some women there may be no other treatment option. Because of ongoing concerns about women’s awareness of the risks, the Medicines and Healthcare products Regulatory Agency (MHRA) has worked with professional bodies, voluntary organisations and patient groups to develop a set of materials to aid communication between health professionals and women and girls.</p><p>The valproate toolkit comprises booklets for healthcare professionals, a reminder card and a guide for women, a checklist for prescribers and clear package labelling carrying a prominent warning about use in pregnancy. The MHRA continues to work with stakeholders to disseminate information and ensure compliance with the statutory advice. On 6 April 2017, NHS Improvement and MHRA sent a Patient Safety Alert through the NHS Central Alerting System to further highlight risks to the unborn child and support the safety of girls and women taking valproate. The alert directs organisations to undertake systematic identification of women and girls taking valproate and to use the MHRA resources to support them to make informed choices. Consistent action was taken in Scotland, Wales, and Northern Ireland.</p><p>The impact of the measures taken is being monitored and studies show a steady decline in prescribing to women in childbearing potential. The adequacy of measures taken to date across Europe is being reviewed in a Europe-wide review that started in March 2017. There are ongoing discussions at official level as the review progresses. An expert working group of the Commission on Human Medicines has been convened to inform the United Kingdom position during the ongoing European Union review and consider other measures which may be required across the healthcare system to ensure compliance with the regulatory position in clinical practice.</p><p>France has its own legislation that allows for a state funded compensation scheme for medical accidents and they have amended this to include claims from those affected by valproate. We understand that this has been operational from June 2017. We are monitoring developments in France and do not feel that commissioning research is necessary at this time. We are not aware of similar action in other member states. There is currently no proposal to establish a care compensation plan specifically for those affected by valproate in the UK. However, the Government has great sympathy for those families who have been affected by the use of valproate in pregnancy. There is support available for families with children born with a disability. The Children and Families Act 2014 introduced a new statutory framework for local authorities and clinical commissioning groups (CCGs) to work together to secure educational, health and social care services for children and young people up to the age of 25 who have special educational needs or a disability (SEND).</p><p>Local authorities and CCGs must commission services jointly around a set of locally agreed outcomes to ensure that the needs of children and young people with SEND are met. Local authorities must also publish a clear, transparent ‘local offer’ of services available which has been developed for, and with, parents and young people. The reforms introduced by the Act are designed to reduce health inequalities, improve the experiences of children and young people with SEND, and their families, and deliver integrated services to achieve improved outcomes.</p><p>The Parliamentary Under Secretary of State for Health (Lord O’Shaughnessy) is meeting with the Chair of the All-Party Parliamentary Group on Anti-epileptic Drugs in Pregnancy to discuss these issues later this year; members of the Independent Fetal Anti Convulsant Trust may wish to attend also.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 106219 106221 106222 106272 106362 106364 106365 106366 106367 question first answered 16/10/2017 16:28:59 answering member 4067 label Biography information for Steve Brine
tabling member	1506 label Biography information for Andrew Gwynne

765450

registered interest
date	06/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy: Sodium Valproate
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will meet the Chair of the All-Party Parliamentary Group on anti-epileptic drugs in pregnancy to discuss the effect of people harmed by sodium valproate prescribed during pregnancy.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	106364
answer	answer is ministerial correction date of answer 16/10/2017 answer text <p>Valproate is an effective treatment for epilepsy and bipolar disorder but should only be used in girls and women of childbearing potential if other treatments are ineffective or not tolerated. For some women there may be no other treatment option. Because of ongoing concerns about women’s awareness of the risks, the Medicines and Healthcare products Regulatory Agency (MHRA) has worked with professional bodies, voluntary organisations and patient groups to develop a set of materials to aid communication between health professionals and women and girls.</p><p>The valproate toolkit comprises booklets for healthcare professionals, a reminder card and a guide for women, a checklist for prescribers and clear package labelling carrying a prominent warning about use in pregnancy. The MHRA continues to work with stakeholders to disseminate information and ensure compliance with the statutory advice. On 6 April 2017, NHS Improvement and MHRA sent a Patient Safety Alert through the NHS Central Alerting System to further highlight risks to the unborn child and support the safety of girls and women taking valproate. The alert directs organisations to undertake systematic identification of women and girls taking valproate and to use the MHRA resources to support them to make informed choices. Consistent action was taken in Scotland, Wales, and Northern Ireland.</p><p>The impact of the measures taken is being monitored and studies show a steady decline in prescribing to women in childbearing potential. The adequacy of measures taken to date across Europe is being reviewed in a Europe-wide review that started in March 2017. There are ongoing discussions at official level as the review progresses. An expert working group of the Commission on Human Medicines has been convened to inform the United Kingdom position during the ongoing European Union review and consider other measures which may be required across the healthcare system to ensure compliance with the regulatory position in clinical practice.</p><p>France has its own legislation that allows for a state funded compensation scheme for medical accidents and they have amended this to include claims from those affected by valproate. We understand that this has been operational from June 2017. We are monitoring developments in France and do not feel that commissioning research is necessary at this time. We are not aware of similar action in other member states. There is currently no proposal to establish a care compensation plan specifically for those affected by valproate in the UK. However, the Government has great sympathy for those families who have been affected by the use of valproate in pregnancy. There is support available for families with children born with a disability. The Children and Families Act 2014 introduced a new statutory framework for local authorities and clinical commissioning groups (CCGs) to work together to secure educational, health and social care services for children and young people up to the age of 25 who have special educational needs or a disability (SEND).</p><p>Local authorities and CCGs must commission services jointly around a set of locally agreed outcomes to ensure that the needs of children and young people with SEND are met. Local authorities must also publish a clear, transparent ‘local offer’ of services available which has been developed for, and with, parents and young people. The reforms introduced by the Act are designed to reduce health inequalities, improve the experiences of children and young people with SEND, and their families, and deliver integrated services to achieve improved outcomes.</p><p>The Parliamentary Under Secretary of State for Health (Lord O’Shaughnessy) is meeting with the Chair of the All-Party Parliamentary Group on Anti-epileptic Drugs in Pregnancy to discuss these issues later this year; members of the Independent Fetal Anti Convulsant Trust may wish to attend also.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 106219 106221 106222 106272 106362 106363 106365 106366 106367 question first answered 16/10/2017 16:29:00 answering member 4067 label Biography information for Steve Brine
tabling member	1506 label Biography information for Andrew Gwynne

765451

registered interest
date	06/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy: Sodium Valproate
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps the Government is taking to reduce the number of babies harmed by valproate prescribed during pregnancy.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	106365
answer	answer is ministerial correction date of answer 16/10/2017 answer text <p>Valproate is an effective treatment for epilepsy and bipolar disorder but should only be used in girls and women of childbearing potential if other treatments are ineffective or not tolerated. For some women there may be no other treatment option. Because of ongoing concerns about women’s awareness of the risks, the Medicines and Healthcare products Regulatory Agency (MHRA) has worked with professional bodies, voluntary organisations and patient groups to develop a set of materials to aid communication between health professionals and women and girls.</p><p>The valproate toolkit comprises booklets for healthcare professionals, a reminder card and a guide for women, a checklist for prescribers and clear package labelling carrying a prominent warning about use in pregnancy. The MHRA continues to work with stakeholders to disseminate information and ensure compliance with the statutory advice. On 6 April 2017, NHS Improvement and MHRA sent a Patient Safety Alert through the NHS Central Alerting System to further highlight risks to the unborn child and support the safety of girls and women taking valproate. The alert directs organisations to undertake systematic identification of women and girls taking valproate and to use the MHRA resources to support them to make informed choices. Consistent action was taken in Scotland, Wales, and Northern Ireland.</p><p>The impact of the measures taken is being monitored and studies show a steady decline in prescribing to women in childbearing potential. The adequacy of measures taken to date across Europe is being reviewed in a Europe-wide review that started in March 2017. There are ongoing discussions at official level as the review progresses. An expert working group of the Commission on Human Medicines has been convened to inform the United Kingdom position during the ongoing European Union review and consider other measures which may be required across the healthcare system to ensure compliance with the regulatory position in clinical practice.</p><p>France has its own legislation that allows for a state funded compensation scheme for medical accidents and they have amended this to include claims from those affected by valproate. We understand that this has been operational from June 2017. We are monitoring developments in France and do not feel that commissioning research is necessary at this time. We are not aware of similar action in other member states. There is currently no proposal to establish a care compensation plan specifically for those affected by valproate in the UK. However, the Government has great sympathy for those families who have been affected by the use of valproate in pregnancy. There is support available for families with children born with a disability. The Children and Families Act 2014 introduced a new statutory framework for local authorities and clinical commissioning groups (CCGs) to work together to secure educational, health and social care services for children and young people up to the age of 25 who have special educational needs or a disability (SEND).</p><p>Local authorities and CCGs must commission services jointly around a set of locally agreed outcomes to ensure that the needs of children and young people with SEND are met. Local authorities must also publish a clear, transparent ‘local offer’ of services available which has been developed for, and with, parents and young people. The reforms introduced by the Act are designed to reduce health inequalities, improve the experiences of children and young people with SEND, and their families, and deliver integrated services to achieve improved outcomes.</p><p>The Parliamentary Under Secretary of State for Health (Lord O’Shaughnessy) is meeting with the Chair of the All-Party Parliamentary Group on Anti-epileptic Drugs in Pregnancy to discuss these issues later this year; members of the Independent Fetal Anti Convulsant Trust may wish to attend also.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 106219 106221 106222 106272 106362 106363 106364 106366 106367 question first answered 16/10/2017 16:29:00 answering member 4067 label Biography information for Steve Brine
tabling member	1506 label Biography information for Andrew Gwynne

765452

registered interest
date	06/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy: Sodium Valproate
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will make it his Department's policy to introduce a care compensation plan similar to plans already introduced in other EU states for people harmed by valproate prescribed during pregnancy since 1973.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	106366
answer	answer is ministerial correction date of answer 16/10/2017 answer text <p>Valproate is an effective treatment for epilepsy and bipolar disorder but should only be used in girls and women of childbearing potential if other treatments are ineffective or not tolerated. For some women there may be no other treatment option. Because of ongoing concerns about women’s awareness of the risks, the Medicines and Healthcare products Regulatory Agency (MHRA) has worked with professional bodies, voluntary organisations and patient groups to develop a set of materials to aid communication between health professionals and women and girls.</p><p>The valproate toolkit comprises booklets for healthcare professionals, a reminder card and a guide for women, a checklist for prescribers and clear package labelling carrying a prominent warning about use in pregnancy. The MHRA continues to work with stakeholders to disseminate information and ensure compliance with the statutory advice. On 6 April 2017, NHS Improvement and MHRA sent a Patient Safety Alert through the NHS Central Alerting System to further highlight risks to the unborn child and support the safety of girls and women taking valproate. The alert directs organisations to undertake systematic identification of women and girls taking valproate and to use the MHRA resources to support them to make informed choices. Consistent action was taken in Scotland, Wales, and Northern Ireland.</p><p>The impact of the measures taken is being monitored and studies show a steady decline in prescribing to women in childbearing potential. The adequacy of measures taken to date across Europe is being reviewed in a Europe-wide review that started in March 2017. There are ongoing discussions at official level as the review progresses. An expert working group of the Commission on Human Medicines has been convened to inform the United Kingdom position during the ongoing European Union review and consider other measures which may be required across the healthcare system to ensure compliance with the regulatory position in clinical practice.</p><p>France has its own legislation that allows for a state funded compensation scheme for medical accidents and they have amended this to include claims from those affected by valproate. We understand that this has been operational from June 2017. We are monitoring developments in France and do not feel that commissioning research is necessary at this time. We are not aware of similar action in other member states. There is currently no proposal to establish a care compensation plan specifically for those affected by valproate in the UK. However, the Government has great sympathy for those families who have been affected by the use of valproate in pregnancy. There is support available for families with children born with a disability. The Children and Families Act 2014 introduced a new statutory framework for local authorities and clinical commissioning groups (CCGs) to work together to secure educational, health and social care services for children and young people up to the age of 25 who have special educational needs or a disability (SEND).</p><p>Local authorities and CCGs must commission services jointly around a set of locally agreed outcomes to ensure that the needs of children and young people with SEND are met. Local authorities must also publish a clear, transparent ‘local offer’ of services available which has been developed for, and with, parents and young people. The reforms introduced by the Act are designed to reduce health inequalities, improve the experiences of children and young people with SEND, and their families, and deliver integrated services to achieve improved outcomes.</p><p>The Parliamentary Under Secretary of State for Health (Lord O’Shaughnessy) is meeting with the Chair of the All-Party Parliamentary Group on Anti-epileptic Drugs in Pregnancy to discuss these issues later this year; members of the Independent Fetal Anti Convulsant Trust may wish to attend also.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 106219 106221 106222 106272 106362 106363 106364 106365 106367 question first answered 16/10/2017 16:29:00 answering member 4067 label Biography information for Steve Brine
tabling member	1506 label Biography information for Andrew Gwynne

765453

registered interest
date	06/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy: Sodium Valproate
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions (a) he, (b) Ministers and (c) officials of his Department have had with their counterparts in the EU regarding valproate.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	106367
answer	answer is ministerial correction date of answer 16/10/2017 answer text <p>Valproate is an effective treatment for epilepsy and bipolar disorder but should only be used in girls and women of childbearing potential if other treatments are ineffective or not tolerated. For some women there may be no other treatment option. Because of ongoing concerns about women’s awareness of the risks, the Medicines and Healthcare products Regulatory Agency (MHRA) has worked with professional bodies, voluntary organisations and patient groups to develop a set of materials to aid communication between health professionals and women and girls.</p><p>The valproate toolkit comprises booklets for healthcare professionals, a reminder card and a guide for women, a checklist for prescribers and clear package labelling carrying a prominent warning about use in pregnancy. The MHRA continues to work with stakeholders to disseminate information and ensure compliance with the statutory advice. On 6 April 2017, NHS Improvement and MHRA sent a Patient Safety Alert through the NHS Central Alerting System to further highlight risks to the unborn child and support the safety of girls and women taking valproate. The alert directs organisations to undertake systematic identification of women and girls taking valproate and to use the MHRA resources to support them to make informed choices. Consistent action was taken in Scotland, Wales, and Northern Ireland.</p><p>The impact of the measures taken is being monitored and studies show a steady decline in prescribing to women in childbearing potential. The adequacy of measures taken to date across Europe is being reviewed in a Europe-wide review that started in March 2017. There are ongoing discussions at official level as the review progresses. An expert working group of the Commission on Human Medicines has been convened to inform the United Kingdom position during the ongoing European Union review and consider other measures which may be required across the healthcare system to ensure compliance with the regulatory position in clinical practice.</p><p>France has its own legislation that allows for a state funded compensation scheme for medical accidents and they have amended this to include claims from those affected by valproate. We understand that this has been operational from June 2017. We are monitoring developments in France and do not feel that commissioning research is necessary at this time. We are not aware of similar action in other member states. There is currently no proposal to establish a care compensation plan specifically for those affected by valproate in the UK. However, the Government has great sympathy for those families who have been affected by the use of valproate in pregnancy. There is support available for families with children born with a disability. The Children and Families Act 2014 introduced a new statutory framework for local authorities and clinical commissioning groups (CCGs) to work together to secure educational, health and social care services for children and young people up to the age of 25 who have special educational needs or a disability (SEND).</p><p>Local authorities and CCGs must commission services jointly around a set of locally agreed outcomes to ensure that the needs of children and young people with SEND are met. Local authorities must also publish a clear, transparent ‘local offer’ of services available which has been developed for, and with, parents and young people. The reforms introduced by the Act are designed to reduce health inequalities, improve the experiences of children and young people with SEND, and their families, and deliver integrated services to achieve improved outcomes.</p><p>The Parliamentary Under Secretary of State for Health (Lord O’Shaughnessy) is meeting with the Chair of the All-Party Parliamentary Group on Anti-epileptic Drugs in Pregnancy to discuss these issues later this year; members of the Independent Fetal Anti Convulsant Trust may wish to attend also.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 106219 106221 106222 106272 106362 106363 106364 106365 106366 question first answered 16/10/2017 16:29:00 answering member 4067 label Biography information for Steve Brine
tabling member	1506 label Biography information for Andrew Gwynne

765454

registered interest
date	06/10/2017
answering body	Department for International Trade
answering dept id	202
answering dept short name	International Trade
answering dept sort name	International Trade
hansard heading	Department for International Trade: USA
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for International Trade, pursuant to the Answer of 15 September 2017 to Question 9154, whether he discussed the Bombardier-Boeing dispute with Commerce Secretary Wilbur Ross during his visit to the US in July 2017.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	106245
answer	answer is ministerial correction date of answer 11/10/2017 answer text <p>We have had Cabinet level engagement with the US Administration and Canadian government. We continue to make efforts alongside the Canadian government to get Boeing into discussions to resolve the case. Ministers across government together with officials have engaged with the US and Canadian administrations and at Bombardier in Canada and Belfast to help in bringing this issue to a solution.</p> answering member constituency Chelsea and Fulham answering member printed Greg Hands question first answered 11/10/2017 12:44:34 answering member 1526 label Biography information for Greg Hands
tabling member	1506 label Biography information for Andrew Gwynne

759754

registered interest
date	12/09/2017
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Police: Greater Manchester
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, what recent discussions she has had with the Greater Manchester Police and Crime Commissioner and the Mayor of Greater Manchester on the level of police resources provided to that city region.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	10100
answer	answer is ministerial correction date of answer 20/09/2017 answer text <p>I recently wrote to all Police and Crime Commissioners and Chief Constables setting out a programme of engagement to better understand the impact of changing demands on the sector and what more can be done to improve productivity and efficiency. As part of this engagement I will be speaking to the Mayor of Greater Manchester.</p><p>The Government protected overall police spending in the 2015 Spending Review, and the 2017/18 police funding settlement maintains that commitment. The Greater Manchester Mayor’s direct resource funding for his Police &amp; Crime Commissioner functions (including council tax precept) is £545.4 million in 2017/18, an increase of £4.2 million on funding levels for 2015/16. It is a matter for Chief Constables, working with their Police and Crime Commissioners, to manage their available resources according to local priorities.</p><p>The Home Office collects and publishes data on the size of the police workforce at police force area level, the latest of which are available here: <a href="https://www.gov.uk/government/statistics/police-workforce-england-and-wales-31-march-2017" target="_blank">https://www.gov.uk/government/statistics/police-workforce-england-and-wales-31-march-2017</a></p> answering member constituency Ruislip, Northwood and Pinner answering member printed Mr Nick Hurd grouped question UIN 10101 question first answered 20/09/2017 13:28:00 answering member 1561 label Biography information for Mr Nick Hurd
tabling member	1506 label Biography information for Andrew Gwynne